◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › N › NGNE

Neurogene Inc (NGNE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Neurogene Inc (NGNE) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 131 employees. Its market capitalization is roughly $758 million. In the fiscal year ended 2025-12-31, NGNE reported $0M in revenue and ($90M) in net income.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.

Interactive charts & full statements →

NGNE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$0M	$0M	$1M	$0M	$0M	$0M	—	—	$25M	—	—	—	—	—	—	—
Gross Profit	—	($3M)	($2M)	($3M)	($3M)	($42M)	($2M)	$0M	$25M	—	—	—	$0M	$0M	$0M	$0M
Gross Margin %	—	—	-251.0%	—	—	—	—	—	100.0%	—	—	—	—	—	—	—
Operating Income (EBIT)	($121M)	($103M)	($83M)	($56M)	($57M)	($51M)	($42M)	($24M)	($24M)	($51M)	($38M)	($21M)	($22M)	($9M)	($8M)	($10M)
Operating Margin %	—	—	-8930.3%	—	—	—	—	—	-94.1%	—	—	—	—	—	—	—
Net Income	($111M)	($90M)	($75M)	($36M)	($55M)	($51M)	($33M)	($69M)	($32M)	($50M)	($37M)	($22M)	($24M)	($9M)	($8M)	($11M)
Net Margin %	—	—	-8123.7%	—	—	—	—	—	-126.3%	—	—	—	—	—	—	—
EBITDA	($106M)	($87M)	($72M)	($33M)	($52M)	($50M)	($31M)	($69M)	($32M)	($50M)	($37M)	($22M)	($22M)	($9M)	($8M)	($11M)
Earnings Per Share (EPS)	$-5.50	$-4.27	$-4.28	$-2.83	$-4.30	$-0.92	$-0.64	$-2.57	$-1.34	$-2.14	$-1.96	$-1.73	$-2.75	$-0.87	$-0.77	$-1.05
Shares Outstanding (M)	23M	21M	18M	13M	13M	55M	52M	27M	24M	23M	19M	13M	9M	10M	10M	10M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGNE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	($1M)	$0M
Gross Profit	—	($1M)	($1M)	($17M)	($19M)	($18M)	($15M)	($16M)
Gross Margin %	—	—	—	—	—	—	1659.1%	—
Operating Income (EBIT)	($37M)	($33M)	($28M)	($24M)	($26M)	($26M)	($22M)	($22M)
Operating Margin %	—	—	—	—	—	—	2325.6%	—
Net Income	($34M)	($31M)	($25M)	($21M)	($22M)	($23M)	($20M)	($20M)
Net Margin %	—	—	—	—	—	—	2109.6%	—
EBITDA	($32M)	($30M)	($24M)	($20M)	($21M)	($22M)	($19M)	($19M)
Earnings Per Share (EPS)	$-1.53	$-1.39	$-1.60	$-0.99	$-1.05	$-1.08	$-1.31	$-1.19
Shares Outstanding (M)	23M	22M	15M	21M	21M	21M	15M	17M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGNE Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($86M)	($77M)	($71M)	($51M)	($53M)	($46M)	($25M)	($15M)	($32M)	($45M)	($30M)	($20M)	($18M)	($8M)	($7M)	($10M)
Capital Expenditures (CapEx)	$1M	$1M	$1M	$0M	$2M	$18M	$2M	$1M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($87M)	($78M)	($71M)	($52M)	($55M)	($65M)	($27M)	($16M)	($32M)	($45M)	($31M)	($20M)	($18M)	($8M)	($7M)	($10M)
FCF Margin %	—	—	-7720.1%	—	—	—	—	—	-126.5%	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGNE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($24M)	($26M)	($17M)	($20M)	($19M)	($21M)	($17M)	($16M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M
Free Cash Flow (FCF)	($24M)	($26M)	($17M)	($20M)	($20M)	($22M)	($18M)	($16M)
FCF Margin %	—	—	—	—	—	—	1904.0%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

NGNE Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$244M	$289M	$336M	$223M	$109M	$101M	$211M	$147M	$78M	$110M	$154M	$113M	$41M	$59M	$2M	$10M
Cash & Cash Equivalents	$112M	$104M	$137M	$148M	$82M	$71M	$193M	$143M	$77M	$52M	$32M	$40M	$15M	$54M	$2M	$9M
Total Liabilities	$27M	$24M	$25M	$37M	$11M	$193M	$19M	$5M	$5M	$11M	$10M	$5M	$5M	$7M	$1M	$1M
Total Debt (Short + Long-Term)	$3M	$3M	$3M	$3M	$1M	$2M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$217M	$265M	$310M	$186M	$99M	($92M)	$191M	$142M	$73M	$99M	$145M	$108M	$36M	$51M	$1M	$9M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NGNE viewer.

Other Companies in BIOTECHNOLOGY

DBVT · DBV Technologies — $776 million
ACHV · Achieve Life Sciences Inc — $776 million
CBIO · Crescent Biopharma, Inc. — $776 million
DSGN · Design Therapeutics Inc — $766 million
MNPR · Monopar Therapeutics Inc — $754 million
ARGX · argenx NV ADR — $62 billion
RVMD · Revolution Medicines Inc — $41 billion
ONC · BeiGene, Ltd. — $40 billion

← NGLFINE All “N” companies NGS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.